Lucid Diagnostics CMO discloses 650K LUCD shares

Lucid Diagnostics Inc. Chief Medical Officer Victoria Lee Tou-ho filed an amended Form 3 updating her equity holdings.

Rhea-AI Filing Summary

Lucid Diagnostics Inc. Chief Medical Officer Victoria Lee Tou-ho filed an amended Form 3 updating her equity holdings. She reports 650,000 shares of Common Stock, representing restricted stock granted under the company’s 2018 Equity Plan with specific future vesting dates.

The restricted stock comprises 200,000 shares granted on November 6, 2023 vesting November 6, 2026; 150,000 shares granted February 20, 2025 vesting May 20, 2028; and 300,000 shares granted February 20, 2026 vesting May 20, 2029, all subject to forfeiture if service requirements are not met. She also holds an employee stock option for 100,000 shares of Common Stock at an exercise price of $1.25 per share, expiring on February 22, 2034, with one-third already vested and the remainder vesting in equal quarterly installments through December 31, 2026.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Lee Victoria Tou-ho

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Employee stock option (right to buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Employee stock option (right to buy) — 100,000 contracts (Direct); Common Stock — 650,000 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with the following grant and vesting schedule: 200,000 (awarded November 6, 2023) that has a single vest date of November 6, 2026; 150,000 (awarded February 20, 2025) that has a single vest date of May 20, 2028; 300,000 (awarded February 20, 2026) that has a single vest date of May 20, 2029. Such restricted stock are subject to forfeiture if the requisite service period is not completed.
2. F2. One third of the option vested on December 31, 2024; the balance vests in eight equal quarterly installments, starting March 31, 2025 and ending on December 31, 2026.

Key Figures

Restricted Common Stock: 650,000 shares Restricted grant 2023: 200,000 shares Restricted grant 2025: 150,000 shares +4 more

7 metrics

Restricted Common Stock 650,000 shares Beneficial ownership reported on Form 3/A

Restricted grant 2023 200,000 shares Granted Nov 6, 2023; single vest date Nov 6, 2026

Restricted grant 2025 150,000 shares Granted Feb 20, 2025; single vest date May 20, 2028

Restricted grant 2026 300,000 shares Granted Feb 20, 2026; single vest date May 20, 2029

Stock option underlying shares 100,000 shares Employee stock option, underlying Common Stock

Option exercise price $1.25 per share Employee stock option (right to buy) exercise price

Option expiration February 22, 2034 Employee stock option expiration date

Key Terms

restricted stock, 2018 Equity Plan, Employee stock option (right to buy), vesting, +1 more

5 terms

restricted stock financial

"Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2018 Equity Plan financial

"restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan"

Employee stock option (right to buy) financial

"security_title": "Employee stock option (right to buy)""

vesting financial

"One third of the option vested on December 31, 2024; the balance vests in eight equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

forfeiture financial

"Such restricted stock are subject to forfeiture if the requisite service period is not completed"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Lucid Diagnostics (LUCD) Form 3/A filing report for Victoria Lee Tou-ho?

The Form 3/A shows Chief Medical Officer Victoria Lee Tou-ho’s current equity holdings, including 650,000 shares of restricted Common Stock and an employee stock option for 100,000 shares at $1.25 per share, providing transparency into her ownership stake and incentives.

How many Lucid Diagnostics (LUCD) shares does Victoria Lee Tou-ho beneficially hold?

Victoria Lee Tou-ho reports beneficial ownership of 650,000 shares of Lucid Diagnostics Common Stock. These shares are structured as restricted stock grants with future vesting dates and are subject to forfeiture if the required service periods are not completed.

What are the vesting terms of Victoria Lee Tou-ho’s restricted stock in Lucid Diagnostics (LUCD)?

Her restricted stock includes 200,000 shares vesting November 6, 2026, 150,000 shares vesting May 20, 2028, and 300,000 shares vesting May 20, 2029. All grants require continued service to avoid forfeiture, aligning compensation with long-term employment.

What stock options does Victoria Lee Tou-ho hold in Lucid Diagnostics (LUCD)?

She holds an employee stock option covering 100,000 shares of Common Stock at a $1.25 exercise price, expiring February 22, 2034. One third vested on December 31, 2024, with the remaining balance vesting in eight equal quarterly installments through December 31, 2026.

Does the Lucid Diagnostics (LUCD) Form 3/A show any recent insider buying or selling?

The Form 3/A reflects holdings rather than recent trades, with transactions categorized as holdings and transaction direction marked as unknown. It primarily details current restricted stock and option positions, not new open-market purchases or sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lee Victoria Tou-ho

(Last) (First) (Middle)

360 MADISON AVENUE

25TH FLOOR

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/23/2026

3. Issuer Name and Ticker or Trading Symbol
Lucid Diagnostics Inc. [ LUCD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)
04/13/2026

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	650,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	(2)	02/22/2034	Common Stock	100,000	$1.25	D

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with the following grant and vesting schedule: 200,000 (awarded November 6, 2023) that has a single vest date of November 6, 2026; 150,000 (awarded February 20, 2025) that has a single vest date of May 20, 2028; 300,000 (awarded February 20, 2026) that has a single vest date of May 20, 2029. Such restricted stock are subject to forfeiture if the requisite service period is not completed.

2. One third of the option vested on December 31, 2024; the balance vests in eight equal quarterly installments, starting March 31, 2025 and ending on December 31, 2026.

Remarks:

The reporting person is filing this amendment solely to report the employee stock option listed in Table II, which was omitted from the original filing.

	/s/ Michael A. Gordon, by power of attorney	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)